NY-PHILIP-MORRIS-INTL
24.9.2020 21:22:05 CEST | Business Wire | Press release
André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit . Calantzopoulos discussed the impact that uncertainty, polarization, hyperpartisanship, and ideology are having on international efforts to overcome pressing global issues. He called for science to be protected from politicization and highlighted the importance of developing open dialogues based on factual scientific objectivity. Calantzopoulos shared PMI’s belief that with the right regulatory encouragement and support from civil society, cigarette sales can end within 10 to 15 years in many countries.
The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.
Excerpts of the remarks by André Calantzopoulos follow:
“Reflecting on the state of our world today and the challenges ahead, four words come to mind: Uncertainty . Polarization. Hyperpartisanship. Ideology.
“These words are not new, but with the COVID crisis, they have gained prominence, moving beyond traditionally contentious sectors such as ours and into the mainstream.
“The lockdowns that sent us into our homes earlier this year, the continued uncertainty we all feel, and the immense socioeconomic pressure caused by the pandemic have increased tensions and reinforced the polarization of both private views and the public discourse.
“And while these past months have revealed how much can be accomplished when people work together, the tendency of individuals to put their self-centered impulses ahead of community wellness remains on display.
“Divisiveness—a binary choosing of sides—not only hinders progress but threatens to thwart it.
“Maybe there is no silver-bullet solution—but to focus on respect for and adherence to facts, dialogue, inclusion, and science could help immensely. It is not enough, however, to simply say ‘follow the facts and the science’ and expect progress to unfold. COVID-19 is just the latest example that proves a tragic truth: Science can be, and is being, weaponized to suit narrow agendas. Science and facts are being held hostage—and distorted—by politics, and people are suffering as a result.
“As a society, we are experiencing a confluence of global existential threats. These threats require collective, multilateral discussions and cooperation—and that can only be achieved through a commitment to open dialogue.
“Absent a commitment to factual scientific objectivity—free of agenda-driven politics—we risk the very real and terrifying prospect of vaccine nationalism, an inability to tackle climate change at scale, and a narrowed chance of delivering solutions that create a fairer and more equitable world.
“In a global world, in a global economic and human system, whether we like it or not, there is no solution in isolation. Individual governments or companies alone cannot bring the necessary change. If we want to make the United Nations Sustainable Development Goals a reality, if we want to protect our populations from the pandemic, including implementing a viable vaccine, we must work together. And most important, we must involve the 7.8 billion people on this planet. How do we do this? We tell them what the real problems are—offering the full facts; we propose solutions they can adopt or adapt; and we incentivize them to act in accordance with this new knowledge. We won’t succeed by keeping them in the dark, by confusing them, or by misleading them.
“Being at the helm of the largest multinational tobacco company as it transforms to deliver a smoke-free future, I experience firsthand how detrimental polarization is to making real progress—in this case, progress in eradicating smoking. And, as a reminder, this concerns more than 1 billion men and women who smoke around the world.
“Today, science-based, innovative products that do not involve combustion offer a better alternative for those men and women who would otherwise continue to smoke. To be clear: These products are not risk-free. And the best choice is never to start smoking or to quit tobacco and nicotine altogether. But for those adults who would otherwise continue to smoke, scientifically validated smoke-free products are a much better choice than cigarettes.
“A future in which cigarettes are obsolete is within reach. In fact, with the right regulatory encouragement and support from civil society, we believe cigarette sales can end within 10 to 15 years in many countries. Yes, that’s right: an end to cigarettes within 10 to 15 years in many countries.
“Unfortunately, political agendas and ideology are slowing progress and keeping millions of people uninformed. Rather than holding an evidence-based conversation on how best to regulate these innovative products to help adult smokers leave cigarettes behind, we are often faced with an ideologically driven resistance from some public health organizations and some NGOs. These organizations allow disinformation to appear as legitimate science. They put dogma before data, and they expend more energy on attacking a company than on helping the human beings who should be at the center of the debate.
“Poorly executed scientific studies, skewed results shaped by bias, and misleading media headlines are now the norm.
“What is the result? Many adults who smoke are confused about these better alternatives and so continue to use cigarettes—the most harmful way of consuming nicotine. This is inexcusable. We must ask: Who will take responsibility for denying these adults access to and accurate information about science-backed innovations? Who will be held responsible for the real-world consequences of dogmatic thinking?
“The issues created by uncertainty, polarization, hyperpartisanship, and ideology are not unique to the tobacco sector. From climate change to food security, we need fact-based conversations and a collaborative, multinational, multi-stakeholder approach to deliver real change. The public has a right to decision-making and information based in science. We cannot allow politically driven, well-funded individuals to prevent the world’s citizens from learning about and accessing smart solutions. Whether we are talking about vaccines, carbon emissions, or tobacco harm reduction, we need science, not rhetoric, to inform policies and regulations.
“Science unites. It has the power to open borders and minds and bring progress. It can propel innovation.
“For Philip Morris International, science has changed our company and is transforming our industry. I am proud to come before you today to say that, already, more than 11.2 million people have switched to our main smoke-free product and stopped smoking . Many more have switched to other smoke-free alternatives that are better than continued smoking. This is a profound public health achievement.
“Governments across the world—in Greece, New Zealand, the United Kingdom, and beyond—are beginning to validate the role better alternatives to continued smoking can play. Earlier this year, the U.S. Food and Drug Administration authorized our electronically heated tobacco system, IQOS , as a modified risk tobacco product. In doing so, the agency found that an exposure modification order is ‘appropriate to promote the public health .’
“But a smoke-free future is not yet guaranteed. Ridding the world of cigarettes will require adherence to science, objectivity, collaboration, and a commitment to accelerate information to the people most directly concerned.
“Many years ago, our industry was challenged to create a better alternative to cigarettes. PMI answered that call. We have transformed our entire company to devise and produce scientifically substantiated better products with the aim of delivering a smoke-free future. Science, data, and fact have led us here.
“People who smoke are responding to our efforts. With the right regulations and related information, they could switch out of cigarettes much faster. Let’s put these people—not politics—at the center of policymaking.
“Science secures progress. It secures solutions. It brings hope at a time when global challenges are so great they threaten to overwhelm. We should not allow science to be politicized and polarized.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2020, PMI estimates that approximately 11.2 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 57 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 18:00:00 CEST | Press release
Partnership Enables Developers To Monetize Games On The Skich Store With Xsolla Handling Payments, Tax Compliance, And Commerce Infrastructure Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
